Immix Biopharma
preclinical data provides translational rationale combination rationale | Immix Biopharma
Company
Deck Type
Sector
Industry
Deck date
March 2024
Slide
45 of 56
Similar slides by Immix Biopharma
See diffirences between slides (animation)
Investor Presentation
January 2024
preclinical data provides translational rationale combination rationale | Immix Biopharma
Investor Presentation
December 2023
preclinical data provides translational rationale combination rationale | Immix Biopharma
Investor Presentation
November 2023
preclinical data provides translational rationale combination rationale | Immix Biopharma
Investor Presentation
November 2023
preclinical data provides translational rationale combination rationale | Immix Biopharma
Related slides by other companies
Aeglea BioTherapeutics
Investor Presentation
May 2023
preclinical data support once weekly dosing of | Aeglea BioTherapeutics
Ocuphire Pharma
Results
October 2022
preclinical data oral blocks | Ocuphire Pharma
Arbutus Biopharma
Results
November 2022
preliminary phase a triple combination data | Arbutus Biopharma
Aeglea BioTherapeutics
Investor Presentation
April 2023
preclinical data support once weekly dosing of | Aeglea BioTherapeutics
Other recent decks by Immix Biopharma
See all presentations (11 decks)
Investor Presentation
January 2024
Investor Presentation
December 2023
Investor Presentation
November 2023
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights